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Abstract 
The current definition of hypertension is based on blood pressure values, and blood pressure also 
drives treatment decisions, is the most important treatment monitoring tool and helps estimating 
risk of hypertension related organ damage. In an era of precision medicine additional biomarkers are 
needed in the diagnosis and management of patients with hypertension. In this review we outline 
the areas in which functional, imaging and circulating biomarkers could help in a more individualised 
definition of hypertension and associated risk. We will cover biomarkers for diagnosis; of 
pathophysiology and prediction of hypertension; response to treatment, organ damage; and to 
monitor treatment. A clear focus is on the vasculature, the heart and the kidneys, whereas we see a 
need to further develop biomarkers of cerebral function in order to diagnose cognition deficits and 
monitor changes in cognition in the future to support addressing the growing burden of 
hypertension associated vascular dementia. 
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Introduction 
Hypertension affects approximately one third of the population worldwide and its prevalence 
is continuously increasing [1, 2]. Hypertension is a major risk factor for cardiovascular morbidity and 
mortality in both sexes. Despite the availability of efficient and well tolerated antihypertensive 
medication for many decades the prevalence of uncontrolled hypertension remains alarmingly high 
[3]. Although even patients with controlled hypertension appear to be at higher cardiovascular risk 
than healthy control subjects, the cardiovascular risk in those with uncontrolled or difficult to control 
hypertension is particularly high [4]. 
Strategies to reduce the global burden of hypertension and associated cardiovascular diseases 
include primary prevention by addressing lifestyle factors, aggressive blood pressure-lowering 
therapy and prevention and treatment of target organ damage. In a highly prevalent condition such 
as hypertension a combination of broad and simple treatment aimed at all patients as well as 
targeted approaches aimed at individual patients appears most promising. In this review we will 
discuss how biomarkers can help in our understanding of the pathophysiology of hypertension, 
guide therapeutic approaches and monitor treatment success. We will not be able to provide a 
comprehensive review of all such biomarkers. Instead, we would like to give an overview of the 
multiple roles that biomarkers can play in hypertension and illustrate these roles with key examples. 
The NIH Biomarker Definitions Working Group defines a biomarker as "a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention" [5]. Characteristics that derive 
from imaging studies or other investigations are included in this definition and are often more 
important in clinical practice than circulating biomarkers. Although many of the biomarkers used in 
hypertension simultaneously evaluate multiple aspects of disease we will discuss these aspects 
separately in this review (Figure). 
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The definition of hypertension is based on a value that can be measured: blood pressure [6, 
7]. Blood pressure is indeed the universal biomarker for hypertension. It can be objectively 
measured, defines the condition, guides therapeutic approaches and is routinely used to assess 
responses to a therapeutic intervention. However, there are areas where additional biomarkers are 
urgently needed. For example, biomarkers can help us understand the complex pathophysiology and 
hence pave the way to development of novel therapeutic strategies; identify individuals requiring 
more intensive treatment; gauge compliance with treatment; and identify secondary forms of 
hypertension. 
 
Diagnostic biomarkers in hypertension 
With the definition of hypertension being based on blood pressure it is difficult to imagine 
which other factors could improve, redefine or even replace the current diagnostic criteria for the 
condition. We will draw some scenarios that highlight the shortcomings of a purely blood pressure-
based definition of hypertension and how additional biomarkers could provide further insights. We 
will focus on primary hypertension as the role of biomarkers in the diagnosis of secondary forms of 
hypertension is clinically established and already part of current [7, 8]. 
 
Dimensions of blood pressure 
Traditionally hypertension has been defined based on office blood pressure readings. In 
recent years the role of out-of-office blood pressure readings in the form of ambulatory blood 
pressure monitoring (ABPM) and home (self) blood pressure monitoring has been recognised [9]. 
More frequent blood pressure readings especially in the form of out-of-office readings allowed the 
recognition of blood pressure variability as a new marker of cardiovascular risk. Increased blood 
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pressure variability, both in the short term (as derived for example from ABPM) and in the long term 
(for example visit-to-visit variability) has been found to be a risk factor for cardiovascular, 
particularly for cerebrovascular, events independent of the level of blood pressure [10] and could be 
a specific therapeutic target [11]. Another novel blood pressure modality is central blood pressure. 
Whilst peripheral blood pressure (for example in the brachial artery where it is most commonly 
measured) is highly correlated with central blood pressure (i.e. blood pressure in the aorta and 
carotid arteries) in larger cohorts [12] substantial differences between central and peripheral blood 
pressure in individual patients have been described. A range of non-invasive devices have been 
developed that derive central blood pressure from peripheral readings and features of the pulse 
waveform, and normal values for central blood pressure have been established [13]. Nevertheless, 
there remains controversy surrounding use of central blood pressure in the diagnosis and treatment 
of hypertension [14, 15]. It is clear, however, that antihypertensive medication can have different 
effects on peripheral and central blood pressure [16] and assessing haemodynamic features beyond 
the traditional measurement of brachial blood pressure is an attractive concept for the management 
of hypertension. 
Independent of the method of assessment the threshold for definition of hypertension is a 
matter of ongoing debate. Fuelled by the recognition that (apart from very low blood pressure) 
there is a continuous relationship between level of blood pressure and cardiovascular risk [17] and 
recent trial evidence of better outcomes in those treated to lower targets [18] there is now debate 
regarding whether the 140/90 mmHg threshold can still be recommended for diagnosis of 
hypertension and as a therapeutic target [19]. With limited resources available and potential risks 
associated with too great a reduction in blood pressure, at least in some groups of patients [20, 21], 
more precise diagnosis and risk stratification of individuals are warranted. 
In summary, whilst hypertension continues to be defined as raised blood pressure the 
phenotype "blood pressure" has evolved considerably in recent years. Not all of these developments 
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have been integrated into clinical practice guidelines which are directed towards the vast majority of 
patients with hypertension who are managed in general practice. However, in an attempt to deliver 
individualised therapies in the future, deeper characterisation of hypertension and the phenotype 
"blood pressure" is required. 
 
Biomarkers of pathophysiology 
Genetic aspects and "omics" 
Genetic components of hypertension have been reviewed extensively elsewhere [22].The 
genome remains stable throughout life and therefore offers the potential to detect increased risk 
already at very early stages and before disease develops. Throughout life the relationship between 
genotype and phenotype can be modified, for example by interaction with environmental factors 
[23], providing the rationale for studies into gene expression and gene regulation as biomarkers of 
hypertension. Transcriptomic profiles that characterise hypertension in rodent models have been 
established [24] and first data in human kidneys point towards differences in the expression of the 
gene encoding renin between hypertensive and normotensive individuals [25]. Studies into the 
regulation of gene expression and in particular into microRNAs are of interest in this context [26]. A 
recent example shows that circulating levels of miR-181a are a surrogate for renal miR-181a 
expression where it colocalises with renin particularly in collecting ducts and that this microRNA is 
differentially regulated between hypertensive and normotensive subjects [27]. 
There is therefore great hope that "higher" omics technologies including transcriptomics, 
proteomics and metabolomics will provide additional and more precise data to describe exactly the 
position of an individual on their path to development of disease. As yet there are, however, only 
limited data available that specifically address hypertension, in part because of the difficulties 
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disentangling blood pressure from its consequences including target organ damage. Nevertheless, 
some metabolites such as hexadecanedioate have been found to be differentially regulated in 
hypertension [28] and the potential of proteomics to impact on cardiovascular health and disease 
has recently been defined [29]. In specific hypertensive conditions such as pre-eclampsia a wealth of 
proteomic and metabolomic data are available that provide some insights into the pathogenesis that 
could also inform our understanding of essential hypertension and other vascular diseases [30-32]. 
 
Renal aspects and the sympathetic nervous system 
There is a particularly close relationship between hypertension and renal function. 
Hypertension can damage the kidneys and thus affect renal function. On the other hand, any 
changes in glomerular filtration rate or tubular reabsorption of water and salt are associated with 
altered renal pressure natriuresis. Thereby a range of signalling pathways including the RAAS, the 
sympathetic nervous system (SNS), reactive oxygen species (ROS), the endothelin system, natriuretic 
hormones, inflammatory cytokines and nitric oxide are all linked to hypertension [33]. Renal function 
in its own right and factors contributing to renal dysfunction could play a role as biomarkers of 
hypertension. 
In this context we would like to draw attention to the revived interest in the role of the SNS in 
the pathogenesis of hypertension, in part fuelled by the initially promising data on renal sympathetic 
denervation to treat patients with resistant hypertension [34]. There is no doubt that SNS activity is 
increased in patients with hypertension but conventional biomarkers such as 24-hour urinary 
catecholamine excretion are not suited to reliably reflect this. More sophisticated techniques such as 
measurement of noradrenaline spillover and of muscle sympathetic nerve activity may be required 
to accurately describe SNS activity although some information can derive from markers such as heart 
rate and plasma noradrenaline levels [35]. The disappointing results of a recent large randomised 
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clinical trial into renal sympathetic denervation [36] has opened discussions not only into the 
technical aspects of the procedure but also into identification of those patients who could benefit 
from sympathetic denervation. In this context biomarkers including markers of SNS activity could 
play a role [37] to explain why some patients experience substantial blood pressure reductions with 
this procedure [38]. 
Another recent development that is not directly related to the kidneys but challenges our 
concepts of the kidneys as the main player in electrolyte and in particular in sodium balance is the 
discovery of the skin and more generally, of the (extrarenal) interstitium as an organ that is critically 
involved in sodium storage and regulation [39]. Whilst opening new insights in the role of sodium in 
the development of hypertension and its interaction with the immune system [40] these findings 
also define interstitial sodium content as a new biomarker that can be measured by magnetic 
resonance imaging [41], is increased in hypertension [42], can be modified e.g. by exercise [43] and 
be a treatment target e.g. using haemodialysis in patients with end-stage renal failure [44]; thereby 
fulfilling all the criteria of a biomarker [5]. 
 
Markers of vascular dysfunction  
The relationship between hypertension and vascular function and structure is equally strong. 
Again, hypertension can cause vascular damage but altered vascular function and structure are also 
critically involved in the pathogenesis of hypertension. This relates to both the small [45, 46] and the 
large vessels [46]. From a biomarker perspective vascular phenotypes are particularly attractive for 
the precise assessment of blood pressure, detection of hypertension-related damage and for 
monitoring of treatment success. However, recent developments in circulating biomarkers of 
vascular function should be highlighted here as they provide insights into the pathophysiology of 
hypertension. 
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Microparticles are small fragments of membrane released from eukaryotic cells that play a 
role as biomarkers of cell activation and stress as well as biovectors that transmit signals between 
cells and between organs [47, 48]. In the context of hypertension microparticles that derive from 
endothelial cells are of particular interest. Differences in numbers and composition of endothelial 
cell derived microparticles have been demonstrated between hypertensive and normotensive 
individuals [49] and antihypertensive and lipid-lowering therapies have been shown to change 
microparticle function [50]. Pre-eclampsia has been subject to a relatively large number of 
microparticle studies [51, 52] providing evidence for their role as mediators of the rapidly developing 
systemic endothelial dysfunction and hypertension in this condition. Microparticles are probably a 
prime example of novel biomarkers that provide insight into the pathophysiology of hypertension 
and vascular dysfunction but are not yet ready for clinical application. This is due to ongoing 
discussions about their precise definition; technical challenges related to their measurement; 
absence of standardised protocols; and lack of clinical data providing evidence for a role of 
microparticles in the management of hypertension over and above measurement of blood pressure. 
There is also development in the discovery of novel vasoactive substances that could serve as 
biomarkers of hypertension and other cardiovascular diseases in the future. Without going into any 
detail we would like to highlight that advances in technology and especially in mass spectrometry 
have made it possible to screen for and detect such novel substances and have led to the 
identification of Angiotensin A [53] and more recently of Vasoconstriction-Inhibiting Factor [54] as 
novel players in the balance between vasoconstriction and vasorelaxation. Other factors including 
arginine vasopressin and its inert prosegment copeptin have been found to be associated with 
essential hypertension [55] and pre-eclampsia [56, 57] but the clinical relevance remains to be 
determined. 
 
Oxidative stress and inflammation 
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In addition to principles that affect specific organs such as the kidneys or the vasculature there 
are pathophysiological mechanisms of a more general nature that are critically involved in the 
development of hypertension. The contribution of reactive oxygen species (ROS) to the pathogenesis 
of endothelial dysfunction but also the development of advanced structural changes such as 
increased vascular stiffness and atherosclerosis is well established [58]. Beyond the vasculature 
altered ROS production plays a crucial role in the kidneys and only recently the contribution of site 
specific expression of sources of ROS such as nicotinamide adenine dinucleotide phosphate reduced 
oxidase 5 (Nox5) in the kidneys has been recognised [59]. From a biomarker perspective ROS are 
attractive as oxidative stress has been found to be involved in all stages of the cardiovascular 
continuum, from early asymptomatic disease to advanced organ damage [60]. The comprehensive 
assessment of a complex phenomenon such as oxidative stress is challenging and multiple 
biomarkers have to be employed. There is evidence that hypertension is associated with increased 
levels of markers of oxidative stress that reflect different sources and actions of ROS [61] but given 
the complex nature of oxidative stress we do not believe that such markers add substantially to the 
management of patients with hypertension at this point in time. Assessment of markers of oxidative 
stress can, however, shed light on the mechanisms that link traditional and novel risk factors such as 
chronic inflammation to the development of cardiovascular diseases. 
Similarly, there has been considerable progress in our understanding of the interplay between 
inflammation and vascular disease in recent years, and immune mechanisms are among the most 
promising targets for novel therapeutic approaches in hypertension [62]. Like oxidative stress, 
inflammation is a complex phenomenon and the immune system contains too many components to 
be represented fully by single biomarkers. Nevertheless, simple biomarkers of inflammation such as 
C-reactive protein are indeed raised in patients with hypertension; these data have been recently 
reviewed elsewhere [63]. 
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Rather than going into further detail of biomarkers of oxidative stress and inflammation we 
would like to mention briefly the role of uric acid as biomarker of hypertension. Uric acid is an 
attractive biomarkers as it can be measured easily and as part of routine clinical biochemistry. Uric 
acid affects endothelial function by mechanisms involving oxidative stress and inflammation and the 
epidemiological basis for an association between raised uric acid levels and hypertension and its 
cardiovascular complications is robust [64-67]. Uric acid has the potential to add to risk stratification 
and serve as a therapeutic target. In the context of uric acid as biomarker of pathophysiology it is 
interesting to note that uric acid-lowering therapy in obese adolescents with prehypertension 
resulted in significant reductions of blood pressure and systemic vascular resistance [68]. These 
individuals are young and do not have established vascular disease or hypertension and the concept 
of interfering with a pathogenetic factor at an early stage of disease is attractive. Whether uric acid 
can play a role as a therapeutic target in established hypertension remains to be determined. Recent 
data using a propensity-matched design in adults with hypertension suggest that exposure to 
allopurinol indeed reduces rates of stroke and cardiac events and provide a basis for the design of 
prospective clinical trials [69]. 
 
Biomarkers to predict development of hypertension 
It appears plausible that biomarkers associated with the pathophysiology of hypertension can 
provide information about development of hypertension in individuals who are (still) normotensive. 
A cluster of clinical risk factors including diabetes, obesity and smoking are known to be associated 
with a higher risk of developing hypertension [70] but additional biomarkers could help to restratify 
this risk and identify those who could benefit most from strategies of primordial prevention. First 
and foremost one might think of genetic factors, and as outlined above there is some potential that 
genomic information could identify those at higher risk – with the caveats of gene-environment 
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interaction and modulation of transcription and translation by other factors to be taken into 
account.  
Within the circulating biomarkers and biomarkers in urine there are data on a cluster of 
markers including C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, aldosterone, 
renin, B-type natriuretic peptide, N-terminal proatrial natriuretic peptide, homocysteine and urinary 
albumin:creatinine ratio that are associated with incident hypertension [71]. Other studies have 
found associations between incident hypertension and parathyroid hormone [72], cardiac troponin T  
[73], plasma bicarbonate [74], uric acid [75], insulin sensitivity [76], lipoprotein particle size and 
subclass concentration [77] and vitamin D [78] – to name a few. 
Clearly these associations are of interest but most of the above data require further 
replication and validation in independent cohorts. And even if confirmed, the therapeutic options to 
prevent hypertension are currently limited. Studies in patients with prehypertension have shown 
that pharmacological treatment can delay the onset of overt hypertension [79, 80] but true 
primordial prevention is currently out of reach. It is possible, however, that precise definition of 
altered biomarker profiles in individual patients can identify dysregulated pathways which could be 
subject to specific preventative therapies instead of the currently employed "general" 
antihypertensive agents. 
 
Biomarkers to predict treatment response 
The effect of individual antihypertensive agents in patients with hypertension is difficult to 
predict. Whilst overall systolic blood pressure reductions of 5 to 10 mmHg per antihypertensive 
agent can be expected the individual response varies. Biomarkers could help to predict blood 
pressure response and thereby avoid cycling through classes of antihypertensive agents in order to 
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find the right drug for a given patient. A very simple algorithm based on age and ethnic background 
of a patient remains the foundation of the National Institute for Health and Care Excellence (NICE) 
guidelines in the UK [https://www.nice.org.uk/guidance/cg127. Accessed 12 March 2016]. Age and 
ethnicity serve as surrogates for renin and thereby RAAS activity and allocate RAAS blockers to those 
in whom the system is more active [81]. This crude strategy has recently been confirmed in the 
PATHWAY-2 Trial where the blood pressure-lowering effect of spironolactone was greatest in 
patients with high levels of plasma renin [82]. 
Other strategies to predict treatment response are based on haemodynamic profiles and 
basically address the fact that vasoconstriction and cardiac output/volume overload contribute to 
varying extents across patients with hypertension and could direct therapy preferentially to 
vasodilators and diuretics, respectively. Small and short-term studies have shown that an 
individualised treatment with antihypertensive agents tailored towards haemodynamic profiles can 
improve blood pressure control [83] or reduce adverse events at similar blood pressure control 
compared to conventional treatment algorithms [84]. 
Some elements of individual responses to antihypertensive therapy will be independent of the 
current state of the organism and can be predicted by genetic factors. However, unlike other 
cardiovascular conditions where pharmacogenetic studies have demonstrated genetically 
determined differences in the metabolism and thereby efficacy of e.g. clopidogrel and warfarin [85], 
pharmacogenetics currently plays less of a role in hypertension. Antihypertensive agents are 
generally well tolerated, affect multiple pathophysiological principles and are thereby less likely 
influenced in their action by specific genetic variants. Some evidence for specific gene variants being 
associated with blood pressure-lowering effects have, however, already been reported [86], and 
whether other genetic variants such as those in the UMOD gene predict treatment response will 
have to be subject of future clinical studies. A promising concept to identify people who more likely 
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respond to certain classes of antihypertensive lies in the study of associations between treatment 
response and a large number of genetic variants in the sense of pharmacogenomics [87, 88]. 
 
Biomarkers to assess complications of hypertension 
There is a continuous relationship between BP and cardiovascular events [17]. In contrast, the 
correlation between level of blood pressure and level of organ damage, e.g. degree of increased left 
ventricular mass, is less close than expected given the causal relationship between blood pressure 
and left ventricular hypertrophy [89]. Additional biomarkers therefore offer the potential to 
reclassify individuals especially in the intermediate risk categories into higher or lower risk of organ 
damage than estimated from blood pressure alone. Providing information independent of blood 
pressure and other risk factors is one of the key requirements for a biomarker that could serve as 
risk stratification tool. A recent example specifically in the area of hypertension is the above 
mentioned finding that blood pressure variability is an independent risk factor particularly for stroke 
– independent of the level of blood pressure [10]. Similar data exist for vascular phenotypes such as 
arterial stiffness [90] and circulating biomarkers [71] although the latter only moderately improve 
prediction of events compared to traditional risk factors including blood pressure. 
It would be beyond the scope of this paper to comprehensively review the assessment of 
target organ damage in people with hypertension. Instead, we would like to focus on assessment of 
early stages of hypertension-related organ damage including subclinical vascular, cardiac and renal 
phenotypes and mention briefly the cerebral consequences of hypertension. We will not 
systematically review the state-of-the-art but rather point towards some of the recent 
developments (Table). 
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Vascular damage 
There is agreement in clinical guidelines that assessment of vascular structure and function 
has the potential to support risk estimation and to guide therapeutic decisions [7]. It is often a 
cascade from endothelial dysfunction as the earliest marker of vascular damage to increased 
vascular stiffness and atherosclerotic burden that describe a continuum of changes in the 
vasculature in response to hypertension. In turn, these changes can also develop in parallel with 
increased blood pressure or even contribute causally to its development. Statements outlining 
clinical characterisation of vascular phenotypes comprehensively [91] or focussing on specific 
aspects such as endothelial dysfunction [92] are available. Advanced phenotyping techniques such as 
pulse wave analysis or measurement of pulse wave velocity do not yet play a role in clinical practice 
although they may help in the assessment of individual patients with difficult-to-control 
hypertension [38]. 
We would like to take the opportunity to highlight two recent developments that have the 
potential to change the assessment of vascular function in the future. First, there has been 
considerable progress in the development of tools to characterise the retinal microvasculature. 
Where traditional methods such as fundoscopy or simple retinal photography only provide 
information on vascular structure there are now techniques such as Scanning Laser Doppler 
Flowmetry that can within seconds assess structure [93] but also provide information on perfusion 
and changes in perfusion in response to experimental stimuli such as nitric oxide synthase inhibition 
or pharmacological treatment [94]. It remains to be determined whether such tools will be available 
for screening of patients with hypertension in the future and whether they will provide information 
in addition to traditional fundoscopy and inform treatment decisions. 
Second, although a large number of circulating biomarkers are available that provide 
information about certain aspects of vascular function and structure there is clearly no single 
biomarker that assesses the state of the vasculature comprehensively and can thereby routinely 
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inform clinical practice. Markers of endothelial cell function and activation such as E-selectin [95] 
and fibrinogen [96] and markers of inflammation such as C-reactive protein [95, 97] have all been 
found to be related to some but not all vascular properties and they cannot replace other tools in 
research or clinical practice [98]. There is hope, however, that novel large-scale biomarker 
experiments based on proteomics and metabolomics can lead to more comprehensive insights into 
the vasculature by assessing and integrating the information from hundreds and thousands of 
features (peptides, proteins, metabolites) [29]. We have recently described the vascular proteome of 
a diabetic mouse model [99] and are currently working on the integration of preclinical and clinical 
proteomic data in order to develop novel biomarkers of vascular disease that could be applied to 
patients with hypertension [http://www.sysvasc.eu. Accessed 12 March 2016] and similar activities 
are underway in other laboratories [29]. 
 
Cardiac damage 
Whilst cardiac conditions can cause changes in blood pressure, high blood pressure also 
affects the heart. Among the subclinical changes in cardiac function and structure are impaired 
diastolic filling of the left ventricle and left ventricular hypertrophy, respectively. Especially for the 
latter there is evidence that it is an independent risk factor for cardiovascular events [100], can 
respond differently to different blood pressure lowering agents [101] and can be a treatment target 
in its own right [102, 103]. Screening methods with ECG based indices of left ventricular hypertrophy 
are commonly recommended [7] whereas more sophisticated methods that involve 
echocardiography or cardiac magnetic resonance imaging (MRI) require expert skills and are 
relatively costly. 
This is where circulating biomarkers could play a role in early detection of cardiac damage. 
There is evidence for markers of collagen turnover [104], brain natriuretic peptides [105-107] and 
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cardiac troponins [107] to be associated with cardiac damage and/or adverse outcome 
independently of blood pressure but the incremental value over blood pressure, traditional risk 
factors and simple screening tests such as ECG currently appears too small to justify their use in 
routine clinical practice. Multidimensional biomarkers that are based on omics techniques have 
again the potential to overcome the limitations of single biomarkers and there is already some 
evidence that proteomic signatures associated with early functional cardiac changes are predictive 
of development of overt heart failure [108]. Clearly such approaches are not yet ready for the clinic 
but with technology developing so rapidly omics based biomarkers may not only get more precise 
but also less expensive in the near future [29]. 
 
Renal damage 
Guidelines recommend serum creatinine and estimated glomerular filtration rate to assess 
renal excretory function and urinary albumin excretion as biomarker of (early) renal damage [7], and 
there is evidence that cystatin C could provide additional information also with regard to 
cardiovascular and risk prediction [109]. These are well established screening tools but as with all 
screening markers there is a balance between sensitivity and specificity that cannot be optimal for 
both. Neither are these markers specific for hypertension-related renal damage nor are they 
sensitive enough to detect the very early stages of renal disease. Whilst this may not be a problem 
for the majority of patients with uncomplicated hypertension there are patients where more 
detailed information about renal function is required. 
Novel imaging biomarkers such as MRI based arterial spin labelling (ASL) [110] and Blood 
Oxygenation Level-Dependent (BOLD) MRI [111] provide deep insight into renal perfusion and 
oxygenation, respectively, that have the potential to inform diagnostic and therapeutic decisions. 
The future will show whether such tools will play a role in the management of patients with 
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hypertension or whether they will remain restricted to research applications or to primary kidney 
disease. The possibility to use BOLD MRI for the diagnosis of renal artery stenosis [112], however, 
demonstrates how such techniques could find their way into clinical practice in hypertension. 
Similarly, out of the large number of circulating biomarkers of that have for example been 
studied in diabetic nephropathy [113] none currently play a role in clinical practice in hypertension. 
It is again the perspective to miniaturise (multiplex) such assays in order to provide a comprehensive 
characterisation of an individual patient’s renal phenotype that could be important in future 
precision medicine. And as above, proteomic approaches in plasma [114] and urine [115] have 
yielded first promising results that may extend to early detection of renal damage, prediction of 
progression rate of renal failure and monitoring of therapeutic approaches [116]. 
 
Cerebral damage 
Most of the efforts in hypertension management have focussed on acute cerebral events, 
where the association between blood pressure and stroke is epidemiologically robust [17], 
pathophysiologically evident [117] and may have therapeutic consequences regarding the choice of 
the best antihypertensive agents for at-risk patients [118]. In recent years an additional focus on the 
association between blood pressure and cognition has developed, and strategies to reduce the 
increasing prevalence of dementia are urgently needed. Epidemiologic evidence points towards an 
association between hypertension and cerebral microvascular damage that is a surrogate of vascular 
dementia [119]. It appears plausible that appropriate blood pressure control can reduce the damage 
to the cerebral vasculature and thus help to combat dementia [120]. However, especially in the 
elderly tight blood pressure control can be associated with side effects including falls [21] and 
cerebral hypoperfusion [121] that pose challenges on antihypertensive therapy. 
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Biomarkers to identify early stages of cerebral damage are urgently needed. The gold standard 
methods of assessing white matter lesions by MRI [122] and positron emission tomography [123] are 
associated with high costs and is restricted to specialist centres and therefore not suitable as 
screening and monitoring tool. In recent years, a number of surrogate biomarkers of white matter 
lesions, altered cerebral perfusion and cognitive decline have been studied but despite being a 
global health challenge this area of research is still underdeveloped. There is, however, evidence on 
a correlation between aortic stiffness and cognition [124] and advanced retinal imaging may provide 
deep insight into the cerebral microvasculature [94, 125]. Out of the circulating biomarkers we 
would just like to highlight recent findings on the correlation between ubiquitin C-terminal 
hydrolase-L1 levels and cerebral white matter lesions [126] and specifically in hypertension, 
circulating vascular cell adhesion molecule-1 can provide information on cerebral blood flow and 
may be identify those at highest risk of falls [127]. Of all possible organ damage related with 
hypertension we see the most urgent need for studies into biomarkers of cognition where available 
data that could inform therapeutic decisions are lacking behind the rapid increase in prevalence of 
dementia. 
 
Biomarkers to monitor therapy 
Blood pressure is not only the universal biomarker of hypertension it is also the target of 
therapeutic approaches in patients with hypertension. Lowering blood pressure has been found to 
reduce cardiovascular risk [128, 129]. This effect is largely independent of the individual factors 
contributing to the pathogenesis of hypertension, and even in patients with secondary forms of 
hypertension stenosis unspecific blood pressure lowering therapy confers survival benefit compared 
to no treatment. 
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We expect that blood pressure reduction will remain the main goal of antihypertensive 
therapy in the foreseeable future. However, there may be opportunities for “disease modifying” 
therapies that address specific pathophysiological factors such as inflammation and oxidative stress 
that require careful characterisation and monitoring based on biomarker profiles. Such treatments 
would then not in the first instance address the symptom “blood pressure” but counteract the 
primary causes of hypertension and thereby lead to reduction of blood pressure in the longer term. 
Such effects have already been shown in patients with autoimmune diseases treated with anti-
inflammatory agents such as infliximab [130]. Similarly, it may be possible in patients with 
hypertension to focus on prevention of organ damage for example by introducing specific 
cardioprotective therapies leading to regression of left ventricular hypertrophy independent of 
blood pressure. It will be difficult to prove a clinical benefit of such strategies and to dissect blood 
pressure lowering effects from organ specific effects of therapeutic agents but if at any point in the 
future such strategies will be tested it is clear that biomarkers will play a crucial role in 
characterisation and monitoring of patients.  
 
Conclusions 
Blood pressure is currently the best biomarker in the management of patients with 
hypertension but provides no insights into the pathogenesis, extent of hypertension-related organ 
damage and may not be the best tool to monitor therapeutic success. Novel imaging modalities and 
circulating biomarkers as well as better understanding of blood pressure modalities such as central 
blood pressure and blood pressure variability will in the future help to individualise preventative and 
therapeutic strategies in patients with hypertension. Blood pressure will not be replaced by other 
biomarkers of hypertension in the foreseeable future but could be complemented by biomarkers 
that provide additional information and this inform more precise medicine. 
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Table 
 Imaging / Structure Imaging / Function Circulating 
Vascular 
Carotid Ultrasound 
Pulse wave velocity 
Retinal imaging / fundoscopy 
Flow-mediated dilatation 
Peripheral arterial tonometry 
Pulse wave analysis 
Pulse wave velocity 
Retinal Scanning Laser Doppler Flowmetry 
Adhesion molecules 
Markers of inflammation 
Markers of collagen turnover 
Markers of oxidative stress 
Cardiac 
Echocardiography 
Cardiac MRI 
Echocardiography 
Cardiac MRI 
ECG 
Cardiac troponins 
Natriuretic peptides 
Markers of collagen turnover 
Proteomic markers 
Renal 
Ultrasound 
MRI 
MR angiography 
Doppler Ultrasound 
Arterial spin labelling MRI 
Blood oxygenation level dependent MRI 
Albuminuria 
Serum creatinine /eGFR 
Cystatin C 
Proteomic markers 
Cerebral MRI MRI Adhesion molecules 
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Positron emission tomography 
Cognitive function tests 
Markers of neuronal damage 
 
Examples of biomarkers to assess hypertension associated damage of the vasculature, the heart, the kidneys and the brain. Markers in bold are currently 
recommended for clinical use whereas markers in regular font are mainly used in research and are not in general clinical care of patients with hypertension. 
ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; MR, magnetic resonance; MRI, magnetic resonance imaging. 
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Figure legend 
Transition from normal blood pressure to hypertension and hypertension associated organ 
damage. 
The figure illustrates factors involved in the pathogenesis of hypertension and the effects of 
hypertension on the vasculature, heart, kidneys and the brain. Being primarily a vascular disorder, 
there is overlap between the effects on organs. For example cerebrovascular disease / stroke and 
dementia could feature both under vascular and cerebral damage. Biomarkers described in this 
review can inform all steps in this figure from explaining pathophysiology to assessment of organ 
damage and provide tools to direct preventative and therapeutic approaches. 
BP, blood pressure; cIMT, carotid intima-media thickness; CKD, chronic kidney disease; CV, 
cardiovascular; EF, ejection fraction; ESRD, end-stage renal disease; LVH, left ventricular 
hypertrophy; RAAS, renin-angiotensin-aldosterone system; TIA, transient ischaemic attack. 
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